29 August 2019
In a pair of articles published in 2019, the LUMEA BxChipTM is highlighted as a tool to enable dramatic operational efficiency gains in histopathology labs, while improving tissue quality for potentially improved diagnostic accuracy.
In “Prostate Biopsy Processing: An Innovative Model for Reducing Cost, Decreasing Test Time, and Improving Diagnostic Material” published in the October issue of The American Journal of Clinical Pathology (AJCP), Dr. Paari Murugan et al. demonstrate the time and cost savings resulting from implementing the BxChip in the University of Minnesota pathology laboratory.
In their article, the authors document how their lab dramatically reduced the amount of time and number of consumables necessary to process 48 prostate biopsy specimens. Using the BxChip they were able to reduce the amount of histotechnologist time needed to process 48 specimens by 75 percent and reduce the number of consumables needed by at least a factor of 6. The paper, referring to the BxChip as the “multiplex method” concludes:
“Our study prospectively analyzed various sample processing and quality metrics between the standard histologic processing protocol and a multiplex method that eliminates tissue handling and allows simultaneous processing of prostate biopsy specimens. The latter not only reduced processing time, reading time, and cost but also allowed for potential improvement in diagnostic accuracy by minimizing tissue loss and nonlinear fragmentation.”
In “Shining a Light on Small Biopsy Handling” – National Society of Histopathology (NSH) author Siobhan Fairgreaves outlines the challenges of handling small biopsy samples in a pathology lab. She also highlights a new solution, the LUMEA BxChip, which will be presented at the upcoming NSH Symposium/Convention in New Orleans this September by Dr Max Maza and Mr Colin John Brewer at their workshop “How to Improve Handling of Small Biopsies.”
In this article, the author cites the challenges of small biopsy samples such as overfixation, tissue fragmentation, and tissue damage. Among the solutions discussed is the use of the LUMEA BxChip – which is manufactured in the European Union (EU) as the Themis Biopsy Chip.
“As well as discussing the current solutions and their key features, Max and Colin will introduce an innovative solution, the Themis Biopsy Chip, which seeks to eliminate a large proportion of the risk associated with manual handling of small biopsies.”
The article also states:
“Research shows great promise for this device, particularly in minimizing non-linear fragmentation and specimen loss of these friable specimens. Intact core length is found to be greatly increased and the diagnostic benefit of being able to observe much more of the tissue intact is that the features of the tumor can be better understood. Finally, the vast reduction in laboratory time and resource required results in cost savings when the Biopsy Chip is implemented.”
Both publications demonstrate the combination of improved operational efficiency as well as the diagnostic benefits of being able to visualize more intact tissue. To learn more, please visit https://www.lumea.org/lab.php
LUMEA’s mission is to standardize and improve cancer diagnostics. It developed the first integrated biopsy-to-digital diagnostic platform that improves tissue handling, modernizes the pathology process, and enables the commercialization of diagnostic artificial intelligence. This Lehi, Utah-based company was founded in 2014 by Dr. Matthew O. Leavitt, a Stanford-trained pathologist.